SK15542003A3 - Topením granulovaný výrobok, spôsob jeho výroby, zmes s jeho obsahom v tuhej tvarovanej farmaceutickej jednotkovej dávkovej forme - Google Patents

Topením granulovaný výrobok, spôsob jeho výroby, zmes s jeho obsahom v tuhej tvarovanej farmaceutickej jednotkovej dávkovej forme Download PDF

Info

Publication number: SK15542003A3
Authority: SK; Slovakia
Prior art keywords: granular product; gaboxadol; product according; melting; hydrophilic
Prior art date: 2001-05-21

Application number

SK1554-2003A

Other languages

English (en)

Slovak (sk)

Inventor

Michiel Onne Elama

Lene Andresen

Per Holm

Original Assignee

H. Lundbeck A/S

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-05-21

Filing date

2002-05-17

Publication date

2004-05-04

2002-05-17 Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S

2004-05-04 Publication of SK15542003A3 publication Critical patent/SK15542003A3/sk

Links

229950004346 gaboxadol Drugs 0.000 title claims abstract description 25
ZXRVKCBLGJOCEE-UHFFFAOYSA-N Gaboxadol Chemical compound C1NCCC2=C1ONC2=O ZXRVKCBLGJOCEE-UHFFFAOYSA-N 0.000 title claims abstract description 24
238000002360 preparation method Methods 0.000 title abstract description 7
238000000034 method Methods 0.000 claims abstract description 14
239000002552 dosage form Substances 0.000 claims abstract description 10
150000003839 salts Chemical class 0.000 claims abstract description 10
239000007787 solid Substances 0.000 claims abstract description 10
239000002253 acid Substances 0.000 claims abstract description 6
238000002844 melting Methods 0.000 claims description 30
230000008018 melting Effects 0.000 claims description 30
239000011230 binding agent Substances 0.000 claims description 18
239000000945 filler Substances 0.000 claims description 18
239000000203 mixture Substances 0.000 claims description 15
238000005469 granulation Methods 0.000 claims description 14
230000003179 granulation Effects 0.000 claims description 14
239000000546 pharmaceutical excipient Substances 0.000 claims description 10
229920002261 Corn starch Polymers 0.000 claims description 9
229920001223 polyethylene glycol Polymers 0.000 claims description 9
239000008118 PEG 6000 Substances 0.000 claims description 8
229920002584 Polyethylene Glycol 6000 Polymers 0.000 claims description 8
239000008120 corn starch Substances 0.000 claims description 8
238000010438 heat treatment Methods 0.000 claims description 8
238000004519 manufacturing process Methods 0.000 claims description 6
239000002202 Polyethylene glycol Substances 0.000 claims description 5
239000012458 free base Substances 0.000 claims description 4
229940124531 pharmaceutical excipient Drugs 0.000 claims description 3
150000003840 hydrochlorides Chemical class 0.000 claims 1
238000007909 melt granulation Methods 0.000 abstract 1
239000004480 active ingredient Substances 0.000 description 18
239000004615 ingredient Substances 0.000 description 12
239000003979 granulating agent Substances 0.000 description 7
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
239000001506 calcium phosphate Substances 0.000 description 6
235000011010 calcium phosphates Nutrition 0.000 description 6
239000008187 granular material Substances 0.000 description 6
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 6
229920002785 Croscarmellose sodium Polymers 0.000 description 5
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 5
229910000389 calcium phosphate Inorganic materials 0.000 description 5
229960001681 croscarmellose sodium Drugs 0.000 description 5
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 5
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 5
239000002245 particle Substances 0.000 description 5
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
229920002472 Starch Polymers 0.000 description 4
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 4
229920000168 Microcrystalline cellulose Polymers 0.000 description 3
229920000881 Modified starch Polymers 0.000 description 3
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 3
238000007906 compression Methods 0.000 description 3
230000006835 compression Effects 0.000 description 3
238000005260 corrosion Methods 0.000 description 3
230000007797 corrosion Effects 0.000 description 3
-1 gaboxadol compound Chemical class 0.000 description 3
229910052742 iron Inorganic materials 0.000 description 3
239000000314 lubricant Substances 0.000 description 3
235000019359 magnesium stearate Nutrition 0.000 description 3
235000019813 microcrystalline cellulose Nutrition 0.000 description 3
239000008108 microcrystalline cellulose Substances 0.000 description 3
229940016286 microcrystalline cellulose Drugs 0.000 description 3
235000019698 starch Nutrition 0.000 description 3
229940032147 starch Drugs 0.000 description 3
239000008107 starch Substances 0.000 description 3
238000003756 stirring Methods 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
239000000654 additive Substances 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
229910000019 calcium carbonate Inorganic materials 0.000 description 2
235000010216 calcium carbonate Nutrition 0.000 description 2
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical class [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
235000011132 calcium sulphate Nutrition 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
239000008121 dextrose Substances 0.000 description 2
239000007884 disintegrant Substances 0.000 description 2
238000009472 formulation Methods 0.000 description 2
150000002334 glycols Chemical class 0.000 description 2
239000008101 lactose Substances 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
238000002156 mixing Methods 0.000 description 2
235000019426 modified starch Nutrition 0.000 description 2
229920001451 polypropylene glycol Polymers 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000008109 sodium starch glycolate Substances 0.000 description 2
229920003109 sodium starch glycolate Polymers 0.000 description 2
229940079832 sodium starch glycolate Drugs 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
150000008163 sugars Chemical class 0.000 description 2
238000005550 wet granulation Methods 0.000 description 2
239000004135 Bone phosphate Substances 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
235000019759 Maize starch Nutrition 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
229920002560 Polyethylene Glycol 3000 Polymers 0.000 description 1
229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
239000004721 Polyphenylene oxide Substances 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
229910000831 Steel Inorganic materials 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
239000008119 colloidal silica Substances 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
229960000913 crospovidone Drugs 0.000 description 1
238000007907 direct compression Methods 0.000 description 1
239000007888 film coating Substances 0.000 description 1
238000009501 film coating Methods 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
239000003906 humectant Substances 0.000 description 1
239000008172 hydrogenated vegetable oil Substances 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
VIOAGOMGEZTUHG-UHFFFAOYSA-L magnesium;2-hydroxyacetate;octadecanoate Chemical compound [Mg+2].OCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O VIOAGOMGEZTUHG-UHFFFAOYSA-L 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
229920000570 polyether Polymers 0.000 description 1
229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
238000012545 processing Methods 0.000 description 1
238000012106 screening analysis Methods 0.000 description 1
238000007493 shaping process Methods 0.000 description 1
208000019116 sleep disease Diseases 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
239000004299 sodium benzoate Substances 0.000 description 1
235000010234 sodium benzoate Nutrition 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
239000007892 solid unit dosage form Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
238000005507 spraying Methods 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000010959 steel Substances 0.000 description 1
238000003860 storage Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
238000012360 testing method Methods 0.000 description 1
239000001993 wax Substances 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
229940100445 wheat starch Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Inorganic Chemistry (AREA)
Neurosurgery (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Anesthesiology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)

SK1554-2003A 2001-05-21 2002-05-17 Topením granulovaný výrobok, spôsob jeho výroby, zmes s jeho obsahom v tuhej tvarovanej farmaceutickej jednotkovej dávkovej forme SK15542003A3 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DKPA200100817		2001-05-21
PCT/DK2002/000332 WO2002094225A1 (en)	2001-05-21	2002-05-17	Granular preparations of gaboxadol

Publications (1)

Publication Number	Publication Date
SK15542003A3 true SK15542003A3 (sk)	2004-05-04

Family

ID=8160520

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1554-2003A SK15542003A3 (sk)	2001-05-21	2002-05-17	Topením granulovaný výrobok, spôsob jeho výroby, zmes s jeho obsahom v tuhej tvarovanej farmaceutickej jednotkovej dávkovej forme

Country Status (26)

Country	Link
US (1)	US20040157876A1 (pl)
EP (1)	EP1389091A1 (pl)
JP (1)	JP2004530695A (pl)
KR (1)	KR20030097890A (pl)
CN (1)	CN1511026A (pl)
AR (1)	AR033896A1 (pl)
AU (1)	AU2002338855B2 (pl)
BG (1)	BG108441A (pl)
BR (1)	BR0209834A (pl)
CA (1)	CA2447603A1 (pl)
CZ (1)	CZ20033269A3 (pl)
EA (2)	EA200700703A1 (pl)
HR (1)	HRP20030950A2 (pl)
HU (1)	HUP0400051A2 (pl)
IL (1)	IL158733A0 (pl)
IS (1)	IS7020A (pl)
ME (1)	MEP6308A (pl)
MX (1)	MXPA03010596A (pl)
NO (1)	NO20035146D0 (pl)
NZ (1)	NZ547636A (pl)
PL (1)	PL366541A1 (pl)
SK (1)	SK15542003A3 (pl)
UA (1)	UA80092C2 (pl)
WO (1)	WO2002094225A1 (pl)
YU (1)	YU92103A (pl)
ZA (1)	ZA200308594B (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2001022941A1 (en) *	1999-09-28	2001-04-05	H. Lundbeck A/S	Melt granulated composition and modified release dosage form prepared from said composition
EP1641456B1 (en)	2003-06-25	2010-03-03	H. Lundbeck A/S	Gaboxadol for treating depression and other affective disorders
TW200528098A (en) *	2003-12-18	2005-09-01	Lundbeck & Co As H	Treatment of insomnia in human patients
GB0402118D0 (en)	2004-01-30	2004-03-03	Merck Sharp & Dohme	Polymorphic forms of a GABAA agonist
EP1848420A4 (en)	2005-01-28	2008-01-23	Merck & Co Inc	POLYMORPH SHAPES OF A GABAA AGONIST
US20080262029A1 (en) *	2005-04-29	2008-10-23	H. Lundbeck A/S	Acid and Base Salt Forms of Gaboxadol
TWI553006B (zh) *	2008-05-30	2016-10-11	賽柯傑尼可有限公司	依託拉嗪(eltoprazine)於治療與神經或心理疾病有關之認知失能之症狀的用途
CN102137667A (zh) *	2008-09-01	2011-07-27	H.隆德贝克有限公司	包含加波沙朵和patl或oat抑制剂的药物组合物
WO2013090452A1 (en) *	2011-12-12	2013-06-20	Orbis Biosciences, Inc.	Sustained release particle formulations
CN108024997A (zh)	2015-07-17	2018-05-11	奥维德医疗公司	用加波沙朵治疗发育障碍的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4315934A (en) *	1979-09-24	1982-02-16	Sandoz Ltd.	Organic compounds
DE19525598C2 (de) *	1995-07-13	1997-09-25	Max Planck Gesellschaft	Schlafmittel
US6649186B1 (en) *	1996-09-20	2003-11-18	Ethypharm	Effervescent granules and methods for their preparation
WO2001022941A1 (en) *	1999-09-28	2001-04-05	H. Lundbeck A/S	Melt granulated composition and modified release dosage form prepared from said composition
US6375982B1 (en) *	2000-07-05	2002-04-23	Capricorn Pharma, Inc.	Rapid-melt semi-solid compositions, methods of making same and method of using same

2002
- 2002-05-17 MX MXPA03010596A patent/MXPA03010596A/es not_active Application Discontinuation
- 2002-05-17 HR HR20030950A patent/HRP20030950A2/hr not_active Application Discontinuation
- 2002-05-17 EP EP02742834A patent/EP1389091A1/en not_active Ceased
- 2002-05-17 HU HU0400051A patent/HUP0400051A2/hu unknown
- 2002-05-17 BR BR0209834-2A patent/BR0209834A/pt not_active IP Right Cessation
- 2002-05-17 UA UA20031110120A patent/UA80092C2/uk unknown
- 2002-05-17 PL PL02366541A patent/PL366541A1/pl not_active Application Discontinuation
- 2002-05-17 NZ NZ547636A patent/NZ547636A/en unknown
- 2002-05-17 ME MEP-63/08A patent/MEP6308A/xx unknown
- 2002-05-17 US US10/478,983 patent/US20040157876A1/en not_active Abandoned
- 2002-05-17 CN CNA028104587A patent/CN1511026A/zh active Pending
- 2002-05-17 YU YU92103A patent/YU92103A/sh unknown
- 2002-05-17 KR KR10-2003-7015136A patent/KR20030097890A/ko not_active Ceased
- 2002-05-17 EA EA200700703A patent/EA200700703A1/ru unknown
- 2002-05-17 AR ARP020101839A patent/AR033896A1/es unknown
- 2002-05-17 CA CA002447603A patent/CA2447603A1/en not_active Abandoned
- 2002-05-17 EA EA200301282A patent/EA009731B1/ru not_active IP Right Cessation
- 2002-05-17 IL IL15873302A patent/IL158733A0/xx unknown
- 2002-05-17 SK SK1554-2003A patent/SK15542003A3/sk not_active Application Discontinuation
- 2002-05-17 CZ CZ20033269A patent/CZ20033269A3/cs unknown
- 2002-05-17 AU AU2002338855A patent/AU2002338855B2/en not_active Ceased
- 2002-05-17 WO PCT/DK2002/000332 patent/WO2002094225A1/en not_active Ceased
- 2002-05-17 JP JP2002590944A patent/JP2004530695A/ja active Pending
2003
- 2003-11-04 ZA ZA200308594A patent/ZA200308594B/en unknown
- 2003-11-10 IS IS7020A patent/IS7020A/is unknown
- 2003-11-19 NO NO20035146A patent/NO20035146D0/no not_active Application Discontinuation
- 2003-12-12 BG BG108441A patent/BG108441A/xx unknown

Also Published As

Publication number	Publication date
BR0209834A (pt)	2004-06-15
CZ20033269A3 (en)	2004-03-17
BG108441A (en)	2005-02-28
EA200700703A1 (ru)	2007-08-31
AR033896A1 (es)	2004-01-07
NO20035146L (no)	2003-11-19
CN1511026A (zh)	2004-07-07
EA009731B1 (ru)	2008-02-28
NZ547636A (en)	2008-03-28
HRP20030950A2 (en)	2005-08-31
US20040157876A1 (en)	2004-08-12
AU2002338855B2 (en)	2007-08-16
EP1389091A1 (en)	2004-02-18
ZA200308594B (en)	2004-11-04
KR20030097890A (ko)	2003-12-31
IS7020A (is)	2003-11-10
YU92103A (sh)	2006-05-25
NO20035146D0 (no)	2003-11-19
MXPA03010596A (es)	2004-03-09
JP2004530695A (ja)	2004-10-07
HUP0400051A2 (hu)	2004-04-28
CA2447603A1 (en)	2002-11-28
EA200301282A1 (ru)	2004-04-29
WO2002094225A1 (en)	2002-11-28
MEP6308A (xx)	2010-02-10
UA80092C2 (en)	2007-08-27
IL158733A0 (en)	2004-05-12
PL366541A1 (pl)	2005-02-07

Legal Events

Date	Code	Title	Description
2010-10-07	FC9A	Refused patent application

Publication	Publication Date	Title
EP1231911B1 (en)	2004-03-10	Directly compressible, ultra fine acetaminophen compositions and process for producing same
KR100905730B1 (ko)	2009-07-01	약제학적 형태의 아토르바스타틴 칼슘, 이의 조성물 및아토르바스타틴 칼슘을 함유하는 약제학적 제형
US4911921A (en)	1990-03-27	High ibuprofen content granulations
PL191166B1 (pl)	2006-03-31	Preparat farmaceutyczny zawierający klodronian, sposób jego wytwarzania i zastosowanie krzemionkowanej celulozy mikrokrystalicznej
EP2242483B1 (en)	2013-02-20	Raloxifene composition
JP5086989B2 (ja)	2012-11-28	Ｎ−［５−（アミノスルホニル）−４−メチル−１，３−チアゾール−２−イル］−ｎ−メチル−２−［４−（２−ピリジニル）フェニル］アセトアミドの医薬製剤
AU2002338855B2 (en)	2007-08-16	Granular preparations of gaboxadol
AU2002338855A1 (en)	2003-05-08	Granular preparations of gaboxadol
JP2026082995A (ja)	2026-05-19	ベムペド酸医薬組成物
JP3170139B2 (ja)	2001-05-28	発泡性錠剤
EP2603288A1 (en)	2013-06-19	Pharmaceutical granulate comprising imatinib mesylate
JPH044297B2 (pl)	1992-01-27
PL208096B1 (pl)	2011-03-31	Kompozycja farmaceutyczna o kontrolowanym uwalnianiu zawierająca chlorowodorek tramadolu i sposób jej wytwarzania
JP3397385B2 (ja)	2003-04-14	崩壊遅延防止錠剤
EP1397125B1 (en)	2005-03-30	Compressible guaifenesin compositions and method for producing them
CZ302157B6 (cs)	2010-11-18	Potahovaná tableta s cyklofosfamidem, zpusob její výroby a zpusob výroby tabletového jádra
JP5873394B2 (ja)	2016-03-01	タンニン酸ベルベリン粒子及びその製造方法、錠剤
JP2023184497A (ja)	2023-12-28	医薬組成物及び溶出性改善方法
KR20200078561A (ko)	2020-07-01	퀴놀린 유도체를 함유하는 약학 조성물
SK9912003A3 (en)	2003-12-02	Pharmaceutical composition containing citalopram
EP4321154A1 (en)	2024-02-14	A tablet of tolvaptan and at least one binder processed with spray granulation
HK1067557A (en)	2005-04-15	Granular preparations of gaboxadol
JPH09110698A (ja)	1997-04-28	経口用医薬組成物の製造法
JP2026503327A (ja)	2026-01-28	医薬製剤、その製造方法及び錠剤用組成物
EA051960B1 (ru)	2025-12-24	Фармацевтическая композиция бемпедоевой кислоты